
US lawmakers are pushing for more scrutiny of Chinese investment in pharmaceuticals and biotechnology, as Washington’s strategic competition with Beijing expands beyond semiconductors and artificial intelligence into the healthcare sector…
View original source — South China Morning Post ↗

